KANASEKI Takayuki

写真a

Affiliation

School of Medicine, Department of Pathology (1)

Job title

Lecturer

Homepage URL

https://researchmap.jp/kanaseki

To the head of this page.▲

Degree 【 display / non-display 】

  • MD/PhD

To the head of this page.▲

Research Experience 【 display / non-display 】

  • 2022.06
    -
    Now

    Sapporo Medical University   附属研究所 免疫プロテオゲノミクス共同研究拠点  

  • 2016
    -
    Now

    Sapporo Medical University   病理学第一講座   Assistant Professor

  • 2013
    -
    2015

    Sapporo Medical University   病理学第一講座   助教

  • 2012
    -
    2013

    Sapporo Medical University   病理学第一講座   特任助教

  • 2008
    -
    2011

    日本学術振興会   特別研究員

display all >>

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Life sciences   Immunology   CANCER IMMUNOLOGY

  • Life sciences   Experimental pathology  

To the head of this page.▲
 

Research Interests 【 display / non-display 】

  • Immunopeptidomics

  • T cell

  • Tumor antigen

  • Cancer Immunotherapy

To the head of this page.▲

Papers 【 display / non-display 】

  • Loss of Tapasin in Tumors Potentiates T‐Cell Recognition and Anti‐Tumor Effects of Immune Checkpoint Blockade

    Keigo Moniwa, Serina Tokita, Toshiyuki Sumi, Hiroshi Saijo, Shintaro Sugita, Kotomi Arioka, Yoshihiko Hirohashi, Hirofumi Chiba, Takayuki Kanaseki, Toshihiko Torigoe

    Cancer Science    2025.02

    Authorship：   Corresponding author

    DOI

  • Identification and Phenotypic Characterization of Neoantigen-Specific Cytotoxic CD4+ T Cells in Endometrial Cancer

    Minami Fusagawa, Serina Tokita, Kenji Murata, Tasuku Mariya, Mina Umemoto, Shintaro Sugita, Kazuhiko Matsuo, Yoshihiko Hirohashi, Tsuyoshi Saito, Takayuki Kanaseki, Toshihiko Torigoe

    Cancer Immunology Research ( American Association for Cancer Research (AACR) )  13 ( 2 ) 171 - 184  2025.02

    Authorship：   Corresponding author

    　View Summary

    Abstract Tumor-reactive CD4+ T cells often accumulate in the tumor microenvironment (TME) in human cancer, but their functions and roles in antitumor responses remain elusive. Here, we investigated the immunopeptidome of HLA class II–positive (HLA-II+) endometrial cancer with an inflamed TME using a proteogenomic approach. We identified HLA-II neoantigens, one of which induced polyclonal CD4+ tumor-infiltrating lymphocyte responses. We then experimentally demonstrated that neoantigen-specific CD4+ tumor-infiltrating lymphocytes lyse target cells in an HLA-II–dependent manner. Single-cell transcriptomic analysis of the TME coupled with T-cell receptor sequencing revealed the presence of CD4+ T-cell clusters characterized by CXCL13 expression. The CXCL13+ clusters contained two subclusters with distinct cytotoxic gene expression patterns. The identified neoantigen-specific CD4+ T cells were found exclusively in one of the CXCL13+ subclusters characterized by granzyme B and CCL5 expression. These results demonstrate the involvement of tumor-reactive CD4+ T cells with cytotoxic function in immune surveillance of endometrial cancer and reveal their transcriptomic signature.

    DOI

  • Single-cell profiling of acral melanoma infiltrating lymphocytes reveals a suppressive tumor microenvironment

    Tomoyuki Minowa, Kenji Murata, Yuka Mizue, Aiko Murai, Munehide Nakatsugawa, Kenta Sasaki, Serina Tokita, Terufumi Kubo, Takayuki Kanaseki, Tomohide Tsukahara, Toshiya Handa, Sayuri Sato, Kohei Horimoto, Junji Kato, Tokimasa Hida, Yoshihiko Hirohashi, Hisashi Uhara, Toshihiko Torigoe

    Science Translational Medicine    2024.12

    DOI

  • Neoantigen prioritization based on antigen processing and presentation

    Serina Tokita, Takayuki Kanaseki, Toshihiko Torigoe

    Frontiers in Immunology ( Frontiers Media SA )  15  2024.11

    Authorship：   Corresponding author

    　View Summary

    Somatic mutations in tumor cells give rise to mutant proteins, fragments of which are often presented by MHC and serve as neoantigens. Neoantigens are tumor-specific and not expressed in healthy tissues, making them attractive targets for T-cell-based cancer immunotherapy. On the other hand, since most somatic mutations differ from patient to patient, neoantigen-targeted immunotherapy is personalized medicine and requires their identification in each patient. Computational algorithms and machine learning methods have been developed to prioritize neoantigen candidates. In fact, since the number of clinically relevant neoantigens present in a patient is generally limited, this process is like finding a needle in a haystack. Nevertheless, MHC presentation of neoantigens is not random but follows certain rules, and the efficiency of neoantigen detection may be further improved with technological innovations. In this review, we discuss current approaches to the detection of clinically relevant neoantigens, with a focus on antigen processing and presentation.

    DOI

  • Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes

    Serina Tokita, Minami Fusagawa, Satoru Matsumoto, Tasuku Mariya, Mina Umemoto, Yoshihiko Hirohashi, Fumitake Hata, Tsuyoshi Saito, Takayuki Kanaseki, Toshihiko Torigoe

    Science Advances   10 ( 38 )  2024.09

    Authorship：   Corresponding author

    DOI

display all >>

To the head of this page.▲

Misc 【 display / non-display 】

  • がん局所におけるCD4+T細胞免疫監視とMHCクラスII抗原

    金関 貴幸

    実験医学   (in press)  2025

  • プロテオゲノミクスHLAリガンドーム解析

    金関 貴幸

    腫瘍内科 ( 科学評論社 )  31 ( 3 ) 289 - 293  2023.03

  • がん免疫療法を理解するための免疫学の知識

    金関 貴幸

    泌尿器care & cure uro-lo : 治療と看護みんなつながるマガジン ( メディカ出版 )  27 ( 3 ) 298 - 303  2022.06

  • ネオアンチゲンの同定とワクチン応用

    金関 貴幸

    実験医学   40 ( 16 ) 2562 - 2567  2022

  • プロテオゲノミクスによるネオアンチゲン・新規がん抗原同定と免疫治療

    金関 貴幸

    腫瘍内科 ( 科学評論社 )  27 ( 5 ) 558 - 562  2021.05

    CiNii

display all >>

To the head of this page.▲

Industrial Property Rights 【 display / non-display 】

  • 腫瘍抗原ペプチド

    金関貴幸、時田芹奈、鳥越俊彦

    Patent

  • 対象由来のネオアンチゲンを選択するための方法

    金関貴幸、時田芹奈、鳥越俊彦

    Patent

  • 腫瘍抗原ペプチド

    鳥越俊彦, 金関貴幸, コーチン ビタリー, 菊地泰弘

    Patent

  • 腫瘍抗原ペプチド

    金関貴幸, 鳥越俊彦, 廣橋良彦, 宮本昇, コーチン ビタリー, 佐藤昇志, 後藤正志

    Patent

  • 腫瘍抗原ペプチド

    佐藤昇志, 鳥越俊彦, 廣橋良彦, 金関貴幸, コーチン ビタリー, 高谷あかり, 後藤正志

    Patent

To the head of this page.▲

Awards 【 display / non-display 】

  • 北海道科学技術奨励賞

    2018  

  • 日本病理学会学術研究賞

    2018  

To the head of this page.▲

Research Projects 【 display / non-display 】

  • ネオ抗原検出技術NESSIEを基盤とした個別化がんワクチン開発

    AMED 次世代がん医療加速化研究事業（P-PROMOTE）応用研究

    Project Year :

    2025.04
    -
    2027.03
     

    Authorship： Principal investigator

  • がん予防法開発を目指したがん共通抗原の標的妥当性の検証

    AMED 革新的がん医療実用化研究事業

    Project Year :

    2024.04
    -
    2027.03
     

    Authorship： Coinvestigator(s)

  • 新しいネオ抗原検出技術による腫瘍特異的CD4+T細胞の機能解析とがん治療応用

    基盤研究（B）

    Project Year :

    2024
    -
    2026
     

    Authorship： Principal investigator

  • ネオ抗原特異的T細胞の分子変化に基づく新規免疫チェックポイント分子の探索

    基盤研究（C）

    Project Year :

    2024
    -
    2026
     

    Authorship： Coinvestigator(s)

  • 新規プロテオゲノミクス技術を応用した真のネオ抗原探索とそのバイオマーカー・治療への応用

    AMED 次世代がん医療加速化研究事業（P-PROMOTE）

    Project Year :

    2023.04
    -
    2025.03
     

    Authorship： Coinvestigator(s)

display all >>

To the head of this page.▲

Presentations 【 display / non-display 】

  • A cryptic antigen derived from the non-coding RNA PVT1 as a target for T-cell-mediated immunotherapy

    Takayuki Kanaseki

    日本癌学会（国際セッション） 

    Presentation date： 2024.09

    Event date：
    2024
    　
    　

  • Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes and characterization of neoantigen-reactive CD4 T cells

    Takayuki Kanaseki

    国際がん免疫シンポジウム（シンポジウム） 

    Presentation date： 2024.03

    Event date：
    2024
    　
    　

  • 免疫プロテオゲノミクスによるがん抗原探索

    金関貴幸

    日本病理学会カンファレンス（シンポジウム） 

    Presentation date： 2023.08

    Event date：
    2023
    　
    　

  • Rapid identification of immunogenic neoantigens using surrogate immunopeptidomes

    Takayuki Kanaseki

    日本癌学会（特別シンポジウム） 

    Presentation date： 2023.09

    Event date：
    2023
    　
    　

  • 臨床的に意義のあるネオアンチゲン探索

    金関貴幸

    日本がん免疫学会（シンポジウム） 

    Presentation date： 2022.07

    Event date：
    2022
    　
    　

display all >>

To the head of this page.▲
 

Committee Memberships 【 display / non-display 】

  • 　
    　
    　

      日本癌学会（評議員）

  • 　
    　
    　

      日本病理学会（評議員 / 病理専門医）

  • 　
    　
    　

      日本臨床ストレス応答学会（評議員）

  • 　
    　
    　

      日本がん免疫学会（評議員）

  • 　
    　
    　

      日本免疫学会（評議員）

To the head of this page.▲